Ipsen Pharma News Today

The FDA granted accelerated approval to Ipsen Pharma’s Iqirvo 80 mg, a first-in-class oral, once-daily peroxisome proliferator-activated receptor agonist for the treatment of primary biliary cholangitis, according to a company release. Originally given breakthrough therapy designation in 2019, Iqirvo (elafibranor, Ipsen/Genfit), is now indicated as second-line therapy in combination with

/PRNewswire/ -- The global protein therapeutics market size is estimated to grow by USD 172.8 billion from 2024-2028, according to Technavio. The market is...

Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of...

/PRNewswire/ -- The "Somatostatin Analogs Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.coms...

Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde® regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically...

- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 -- Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the Fiscal Year 2023, including $429 million for the Fourth Quarter of 2023 -- GAAP Diluted EPS of $0.27 for the Fourth Quarter o...

Exelixis (NASDAQ:EXEL – Get Free Report) and Editas Medicine (NASDAQ:EDIT – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation. Analyst Recommendations This is a summary of recent ratings […]

- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 - - Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the...

Exelixis, Inc. today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones....

/PRNewswire/ -- The gastrointestinal stromal tumors therapeutics market is anticipated to grow by USD 1.02 billion, progressing at a CAGR of 6.01% during the...